MedPath

Phase II study of reduced-dose craniospinal irradiation and combination chemotherapy in treating pediatric patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumors

Phase 2
Conditions
medulloblastoma or supratentorial primitive neuroectodermal tumors
Registration Number
JPRN-UMIN000000545
Lead Sponsor
Japanese Pediatric Brain Tumor Consortium
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
100
Inclusion Criteria

Not provided

Exclusion Criteria

Has double cancer. Has cardiac disease for which treatment is necessary.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
3-year progression-free survival
Secondary Outcome Measures
NameTimeMethod
3-year overall survival
© Copyright 2025. All Rights Reserved by MedPath